Atria Wealth Solutions Inc. Sells 1,129 Shares of Kenvue Inc. (NYSE:KVUE)

Atria Wealth Solutions Inc. cut its holdings in Kenvue Inc. (NYSE:KVUE) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,379 shares of the company’s stock after selling 1,129 shares during the period. Atria Wealth Solutions Inc.’s holdings in Kenvue were worth $396,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Clearstead Advisors LLC bought a new position in Kenvue in the third quarter worth about $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue in the 4th quarter valued at approximately $27,000. EverSource Wealth Advisors LLC bought a new stake in shares of Kenvue during the third quarter valued at approximately $28,000. Venturi Wealth Management LLC purchased a new stake in Kenvue in the third quarter worth $28,000. Finally, Cullen Frost Bankers Inc. bought a new position in Kenvue in the third quarter worth $29,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on KVUE shares. William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, The Goldman Sachs Group started coverage on Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $24.85.

Kenvue Price Performance

KVUE opened at $20.08 on Wednesday. The firm has a 50 day moving average price of $19.85 and a 200-day moving average price of $20.11. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue’s revenue for the quarter was down 2.7% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.98%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.